Company intelligence / Profile preview
Genentech
South San Francisco, California, United Statesgene.com ↗
- Ownership
- Private
- Employees
- ~15000
- Development stage
- Commercial
01
Overview
Genentech has multiple FDA-approved products on the market including Tarceva for lung and pancreatic cancer, Lucentis for AMD, Actemra for rheumatoid arthritis, Zelboraf for melanoma, Erivedge for basal-cell carcinoma, and Perjeta for breast cancer
- Therapeutic areas
- OncologyPulmonologyEndocrinologyImmunologyOphthalmologyNeurology
- Modalities
- Monoclonal antibodiessmall moleculesrecombinant DNA technology
- Industry
- Pharma
02
Drug pipeline
189 assets188 more assets in the full pipeline.
Request access →03
Partnerships
Eli Lilly (insulin/Humulin)Novartis (Xolair)
Beyond the preview
Go deeper on Genentech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genentech.